Takeda Presents Positive Results from Phase 3 Study of Vedol

Takeda (TSE:4502/NYSE:TAK) today announced late-breaking data from the Phase 3 GRAPHITE study presented at the 2023 Tandem Meetings, demonstrating vedolizumab achieved a statistically significant and clinically meaningful improvement in lower gastrointestinal (GI) aGvHD-free survival by Day 180 after allo-HSCT with no relevant differences in safety profile versus placebo.1

Related Keywords

United States , Osaka , Japan , Japanese , American , Bin Chen , John Cunningham , Jun Saito , Cancer Center , International Blood Marrow Transplant Research , Hematopoietic Cell Transplant Therapy Program , Exchange Commission , European Union , European Medicines Agency , Takeda Pharmaceutical Company Limited , Met Its Primary Efficacy Endpoint , Clinically Meaningful Intestinal , Free Survival , New Safety Signals Were Seen , Vedolizumab Compared , Patients Who Received , Were Presented , Late Breaking Abstract , Cellular Therapy Meetings , American Society , Cellular Therapy , International Blood , Marrow Transplant Research , Yi Bin Chen , Hematopoietic Cell Transplant , Cell Therapy Program , Mass General Cancer , Safety Information , Special Precautions , Site Reactions , Product Characteristics , Prescribing Information , Medication Guide , Rare Genetics , Plasma Derived Therapies , Annual Report , Lower Gastrointestinal , Acute Graft Versus Host Disease , From Unrelated Donors , Multicenter Study , From Pharmacological Prophylaxis , Intestinal Acute Graft Versus Host Disease , Annexi Summary , For Medicinal Products Human , Pharmacol Exp , Vedolizumab Patient Exposure , Media Contact , Takeda Pharmaceutical , Hase 3 Study Of Vedolizumab , Graft Versus Host , Revention Of Intestinal Acute , Agvhd , Allogeneic Hematopoietic Stem Cell Transplantation , Allo Hsct , Hase 3 Graphite Study , Eaningful Intestinal Agvhd Free , A Late Breaking Abstract , Llo Hsct Data , American Society For Transplantation And Cellular Therapy , Astct , Enter For International Blood Marrow Transplant Research , Cibmtr ,